Core Insights - BlackBerry Limited is set to release its second-quarter earnings results on September 25, with analysts expecting earnings of 1 cent per share and projected revenue of $122.03 million, down from $145 million a year earlier [1] Group 1: Earnings Expectations - Analysts anticipate BlackBerry will report quarterly earnings of 1 cent per share [1] - Projected quarterly revenue is $122.03 million, a decrease from $145 million reported in the same quarter last year [1] Group 2: Recent Developments - On September 18, BlackBerry became the first mobile device management vendor certified by Germany's Federal Office for Information Security (BSI) [2] - Following this announcement, BlackBerry shares fell by 3% to close at $4.27 [2] Group 3: Analyst Ratings - RBC Capital analyst Paul Treiber maintained a Sector Perform rating and raised the price target from $3.75 to $4 [6] - Canaccord Genuity analyst Kingsley Craner maintained a Hold rating and increased the price target from $4.25 to $4.60 [6] - Baird analyst Luke Junk maintained a Neutral rating and raised the price target from $4 to $5 [6] - CIBC analyst Todd Coupland maintained an Outperformer rating but reduced the price target from $7 to $6 [6]

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on CRISPR Therapeutics AG (CRSP), and highlights the potential misalignment of interests between brokerage analysts and retail investors [1][5][10]. Group 1: Brokerage Recommendations for CRISPR Therapeutics - CRISPR Therapeutics has an average brokerage recommendation (ABR) of 1.92, indicating a consensus between Strong Buy and Buy, based on 28 brokerage firms [2]. - Out of the 28 recommendations, 15 are classified as Strong Buy, while one is classified as Buy, representing 53.6% and 3.6% of total recommendations respectively [2]. Group 2: Limitations of Brokerage Recommendations - Studies indicate that brokerage recommendations may not effectively guide investors in selecting stocks with the highest price increase potential [5]. - Brokerage firms often exhibit a strong positive bias in their ratings due to vested interests, leading to a disproportionate number of Strong Buy recommendations compared to Strong Sell recommendations [6][10]. Group 3: Zacks Rank as an Alternative Indicator - Zacks Rank categorizes stocks into five groups based on earnings estimate revisions, which are more reliable indicators of near-term stock price performance compared to ABR [8][11]. - The Zacks Rank is updated more frequently and reflects timely changes in earnings estimates, unlike the potentially outdated ABR [13]. Group 4: Current Earnings Estimates for CRISPR Therapeutics - The Zacks Consensus Estimate for CRISPR Therapeutics remains unchanged at -$6.57 for the current year, suggesting stable analyst views on the company's earnings prospects [14]. - Due to the unchanged consensus estimate, CRISPR Therapeutics holds a Zacks Rank of 3 (Hold), indicating a cautious approach despite the Buy-equivalent ABR [15].

Company Overview - Archrock Inc. has transitioned from a broader energy services provider to a specialized pure-play compression services company, focusing on natural gas production, processing, and transportation [11] - The company has undergone an operational transformation over the past decade to enhance performance, safety, customer service, and environmental responsibility [11] Zacks Rank and Style Scores - Archrock is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of B, indicating a solid position but not a strong buy [12] - The Value Style Score for Archrock is B, supported by a forward P/E ratio of 15.29, making it attractive for value investors [12] - Recent upward revisions in earnings estimates by two analysts for fiscal 2025 have increased the Zacks Consensus Estimate by $0.02 to $1.57 per share [12] - Archrock has demonstrated an average earnings surprise of +6.5%, indicating potential for positive performance [12] Investment Consideration - With a solid Zacks Rank and favorable Value and VGM Style Scores, Archrock is recommended for investors' consideration [13]

Core Viewpoint - Lumentum Holdings Inc. is expected to report significant growth in earnings and revenue for the fourth quarter, indicating a positive outlook for the company [1]. Financial Performance - Analysts predict Lumentum will report quarterly earnings of 81 cents per share, a substantial increase from 6 cents per share in the same quarter last year [1]. - The projected quarterly revenue is $469.92 million, compared to $308.3 million a year earlier, reflecting a strong year-over-year growth [1]. Company Developments - On August 7, Lumentum announced the expansion of its U.S.-based semiconductor facility, which may enhance its production capabilities and market position [2]. Stock Performance - Lumentum shares experienced a slight decline of 1.1%, closing at $115.03 on Monday [3]. Analyst Ratings - Morgan Stanley maintained an Equal-Weight rating and raised the price target from $85 to $92 [8]. - Susquehanna maintained a Positive rating and increased the price target from $95 to $125 [8]. - JP Morgan maintained an Overweight rating and boosted the price target from $100 to $123 [8]. - Wolfe Research initiated coverage with an Outperform rating [8]. - Rosenblatt maintained a Buy rating with a price target of $105 [8].

Core Viewpoint - Moderna is facing challenges due to declining COVID-19 vaccine sales and market uncertainty, leading to workforce reductions and expected financial losses in the upcoming earnings report [2]. Financial Performance - Analysts predict Moderna will report a quarterly loss of $2.97 per share, an improvement from a loss of $3.33 per share a year ago [1]. - Projected quarterly revenue is $112.96 million, down from $241 million a year earlier [1]. Workforce Reduction - Moderna announced plans to reduce its global workforce by approximately 10% by the end of the year [2]. Stock Performance - Following the announcement of workforce reductions, Moderna shares fell by 8.1%, closing at $29.56 [2]. Analyst Ratings - JP Morgan analyst Jessica Fye maintained an Underweight rating and reduced the price target from $33 to $26 [8]. - Evercore ISI Group analyst Cory Kasimov maintained an In-Line rating and cut the price target from $50 to $32 [8]. - Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and lowered the price target from $39 to $32 [8]. - Citigroup analyst Geoff Meacham initiated coverage with a Neutral rating and a price target of $40 [8]. - Argus Research analyst John Eade downgraded the stock from Buy to Hold [8].

Company Overview - LATAM Airlines is the leading airline in Latin America, headquartered in Santiago, Chile [11] - The company filed for Chapter 11 bankruptcy on May 26, 2020, and successfully emerged from bankruptcy on November 3, 2022, as part of a financial restructuring to reduce debt and adapt to challenges from the COVID-19 pandemic [11] - Post-bankruptcy, LATAM emerged with approximately $2.2 billion in liquidity and a 35% reduction in debt, alongside a more resilient operational structure [11] Investment Potential - LATAM Airlines holds a 2 (Buy) rating on the Zacks Rank, with a VGM Score of A, indicating strong investment potential [12] - The company is particularly appealing to growth investors, with a Growth Style Score of A, forecasting year-over-year earnings growth of 29.1% for the current fiscal year [12] - An analyst has revised their earnings estimate upwards for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.05 to $4.17 per share [12] - LATAM has an average earnings surprise of +4%, further enhancing its attractiveness to investors [12] Conclusion - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, LATAM Airlines is recommended for investors' consideration [13]

Group 1 - Etsy, Inc. is set to release its fourth-quarter earnings results on July 30, with analysts expecting earnings of 49 cents per share, an increase from 41 cents per share in the same period last year [1] - Projected quarterly revenue for Etsy is $647.63 million, slightly down from $647.81 million a year earlier [1] - On June 12, Etsy announced a $650 million offering of convertible senior notes [1] Group 2 - Etsy shares experienced a decline of 3.9%, closing at $60.30 [2] - Analysts have provided various ratings and price target adjustments for Etsy, with Stifel maintaining a Hold rating and raising the price target from $45 to $66 [4] - Canaccord Genuity maintained a Buy rating and increased the price target from $62 to $68, while Raymond James raised its Outperform rating target from $50 to $70 [4] - Deutsche Bank maintained a Hold rating with a price target increase from $40 to $47, and UBS raised its Neutral rating target from $45 to $62 [4]

Group 1 - Automatic Data Processing, Inc. (ADP) is expected to report fourth-quarter earnings of $2.23 per share, an increase from $2.09 per share in the same period last year [1] - The projected quarterly revenue for ADP is $5.05 billion, compared to $4.77 billion a year earlier [1] - In the third quarter, ADP reported revenues of $5.55 billion, surpassing the analyst consensus estimate of $5.49 billion [2] Group 2 - BMO Capital analyst Daniel Jester initiated coverage on ADP with a Market Perform rating and a price target of $340 [8] - Morgan Stanley analyst James Faucette maintained an Equal-Weight rating and raised the price target from $305 to $310 [8] - Mizuho analyst Dan Dolev maintained an Outperform rating and increased the price target from $321 to $332 [8] - RBC Capital analyst Ashish Sabadra reiterated a Sector Perform rating with a price target of $315 [8] - TD Securities analyst Bryan Bergin maintained a Hold rating and raised the price target from $298 to $321 [8]

Group 1 - Northrop Grumman Corporation is set to release its second-quarter earnings results on July 22, with expected earnings of $6.68 per share, an increase from $6.36 per share in the same period last year [1] - The company is projected to report quarterly revenue of $10.15 billion, slightly down from $10.22 billion a year earlier [1] - On May 29, Northrop Grumman issued $1 billion in new senior notes, divided into two tranches maturing in 2030 and 2035 [2] Group 2 - Northrop Grumman shares experienced a decline of 0.7%, closing at $515.29 [2] - Recent analyst ratings show a downgrade from Deutsche Bank from Buy to Hold, with a price target reduction from $580 to $542 [8] - Other analysts have maintained or adjusted their ratings and price targets, with Wells Fargo reducing its target from $547 to $525, RBC Capital from $575 to $550, and Truist Securities from $600 to $550 [8]

Group 1 - Zacks Premium offers various tools for investors to enhance their stock market confidence and investment strategies [1][2] - The Zacks Style Scores are complementary indicators that help investors select stocks likely to outperform the market in the next 30 days [3][4] Group 2 - The Style Scores categorize stocks into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment characteristics [4][5][6][7] - The Zacks Rank is a proprietary stock-rating model that utilizes earnings estimate revisions to assist in portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.62% since 1988 [8][10] Group 3 - Enbridge Inc. is a leading energy infrastructure company with a vast pipeline system, transporting 3 million barrels of crude oil daily, accounting for nearly 63% of Canadian crude oil production to the U.S. [12] - Enbridge holds a 3 (Hold) rating on the Zacks Rank, with a VGM Score of B and a Momentum Style Score of A, indicating potential for upward movement [13][14]